Feature | August 25, 2011

Occlutech Announces Closing of 15 Million Euro Financing

August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to market. The European company develops medical implants to treat structural heart disease such as atrial septal defects and patent foramen ovale (ASD and PFO) and left atrial appendage (LAA) occluders.


The funding follows a May 2011 German Supreme Court (BGH) decision to throw out a patent case against Occlutech filed by competitor AGA/St. Jude. AGA also filed claims in several other European countries, all of which have so far been favorable for Occlutech. The company said it intends to initiate litigation for substantial damages against AGA/St. Jude.


In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus artery (PDA) and ventricular septal defect (VSD) in addition to second-generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder and a new generation of stent grafts and cardiac valve intervention technologies are being developed.


The new funding came from an investment lead by Hong Kong-based Interlink Investments Ltd. and subscribed by investors as well as Occlutech distribution partners from Japan, Switzerland, Ireland, Austria and Turkey.


“This investment will allow us to accelerate our R&D and bring new, relevant products to the market in the near future,” said Tor Peters, Occlutech CEO. “In addition we expect substantial payments by AGA-St.  Jude as a result of litigation initiated by AGA in 2006 and culminating in a win for Occlutech in the German Supreme Court in 2011. The additional funding will allow us to aggressively respond to any new, similar litigation initiated in an attempt to divert our attention and resources from creating relevant products that support our customers in their quest to improve and save patient lives."


For more information: www.occlutech.com


Related Content

sentraheart lariet, LAA occlusion, FDA safety alert
Feature | Left Atrial Appendage (LAA) Occluders| July 13, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers and patients of reports of patient deaths...
SentreHeart, Lariat Suture Delivery Device, FDA, AMAZE Trial, AFib, LAA
News | Left Atrial Appendage (LAA) Occluders| July 01, 2015
SentreHeart Inc. announced that it has received approval for an Investigational Device Exemption (IDE) from the U.S....
ACC, HRS, SCAI, left atrial appendage occlusion, recommendations
Feature | Left Atrial Appendage (LAA) Occluders| June 30, 2015
The American College of Cardiology (ACC), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and...
Videos | Structural Heart| June 26, 2015
Interview with Steve Goldstein, M.D., director, noninvasive lab, Medstar Washington Heart Institute, Washington, D.C.
Videos | Cardiovascular Ultrasound| June 17, 2015
Role of Interventional Echcardiography in Transcatheter Structural Heart Procedures — Rebecca Hahn, M.D., Columbia Un
Videos | Structural Heart| June 17, 2015
Interview with Ted Feldman, M.D., FACC, MSCAI, FESC, cardiac cath lab director, Evanston Hospital, North Shore Health
Videos | Structural Heart| June 17, 2015
Interview with Charanjit Rihal, M.D., chief of cardiology and professor of medicine, Mayo Clinic, at the Transcathete
Boston Scientific, investors, cardiology, growth, expansion
News | May 11, 2015
Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a...
Watchman, LAA, left atrial appendage

The Watchman LAA occluder being implanted in the left atrial appendage via a delivery catheter through a transseptal puncture.

Feature | Left Atrial Appendage (LAA) Occluders| April 30, 2015 | Dave Fornell
The long awaited U.S. Food and Drug Administration (FDA) approval of the first transcatheter left atrial appendage (LAA...
Watchman, Mount Sinai, first, eastern United States, implant
News | March 25, 2015
Mount Sinai experts were the first in the eastern United States on March 23 to implant the Watchman device, a newly U.S...
Overlay Init